Prognostic value of EGFR mutation in NSCLC in surgical stage

Introduction: EGFR mutation, has been recognized as a prognostic and predictive factor of response to treatment with tyrosine kinase inhibitors in non-small cells lung carcinoma (NSCLC) at advanced stages, however little is known about their prognostic value in operable disease. Objective: Evaluate if the presence of EGFR mutation influences the progression-free survival (PFS) and overall survival (OS) in patients with NSCLC in surgical stage Methods: Retrospective study conducted by consulting patients clinical files between 01/01/2006 to 31/12/2012, in which the study of EGFR mutation was performed and maintained in follow-up until 31/12/2013. Data analyzed: demographic, smoking history, diagnostic, EGFR, surgery and complications; PFS and OS. Results: 63 patients (70% men), 14.3% EGFR positive. Mean age: 62.06 (+ / - 10.62) years. 27% non-smokers, 35% smokers and 38% former smokers. Histology: adenocarcinoma (81%), squamous (12.7%) and large cell (6.3%). EGFR positive population presented a median PFS of 62.8 months and wild type patients of 44.4 months (p = 0.595). Mean OS in EGFR positive was 77.2 months and in wild type patients was 69.9 months (p = 0.309). EGFR mutation was not associated with increased OS or PFS according to the following OR ((SLP) 1.07 95% CI 0.2 to 5, OR (SG): 8 95% 0, 3 to 24). When we evaluated the PFS according to the pathological stage, we see that the early stages are associated with an increased PFS (p = 0.011). Discussion: In our series, in patients with surgical stage, pathological stage of the disease appears to have a greater prognostic value for relapse than mutational status of EGFR. EGFR mutation was not associated with an increase in PFS or OS in patients with NSCLC in surgical stage.